Zicom Group invests in Singapore growth phase medtech Histoindex
Zicom Group and Singapore Government agency SPRING Singapore will jointly make their first investment of S$2 million (A$1.9 million) into growth phase medtech start-up Histoindex Pte Ltd.
Histoindex’s state-of-the-art technology is focused on imaging and quantitative analysis of unstained liver tissues for liver fibrosis and cancers which can enable personalised treatment.
The technology has been validated by more than 2,000 patients in China, Europe and U.S. and can be expanded to cover multi-organs as part of its technology road map.
The joint venture is developing a Liver Cloud to digitize the technology as a platform to integrate the entire potential Chinese market that is made up of patients, hospitals, healthcare institutions, research institutes, pharmaceutical suppliers and potentially developing it into an on-line transactional medium for the various users.